FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| 1% preservative-free lidocaine | Pain Reduction | PHASE4 | WITHDRAWN |
| Omidria | Cataract | PHASE4 | COMPLETED |
| Phenylephrine 1.0%/ Ketorolac 0.3% | Pain Reduction | PHASE4 | WITHDRAWN |
| Vehicle | Meniscal Tear | PHASE3 | COMPLETED |
| OMS103HP | Knee Injuries | PHASE3 | COMPLETED |
| OMS103HP-S | Meniscal Tear | PHASE3 | COMPLETED |
| Phenylephrine HCl | Unilateral Cataract Extraction | PHASE3 | COMPLETED |
| OMS302 | Unilateral Cataract Extraction | PHASE3 | COMPLETED |
| Part 2 OMS302 | Intraocular Lens Replacement | PHASE3 | TERMINATED |
| Part 1 OMS302 | Intraocular Lens Replacement | PHASE3 | TERMINATED |
OMER holds $2M in cash and burns about $5.2M/quarter from operations, giving an estimated runway of 1.2 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for OMER free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-07-24 | Borges David J. |
Purchase | $0 |
| 2026-07-24 | Cancelmo Peter B |
Purchase | $0 |
| 2026-07-24 | Demopulos Gregory A MD |
Purchase | $0 |
| 2026-06-22 | HANISH ARNOLD C |
Purchase | $0 |
| 2026-06-22 | Bumol Thomas F. |
Purchase | $0 |
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-05-06 | Narsoplimab | BLA | -7.5% | -6.9% | -44.2% |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for OMER and 2 more tickers of your choice.
Create Free Account →